Libre Duo FDA Authorisation Through De Novo Pathway
Abbott’s Libre Duo FDA authorisation creates a new Class II device category, combining glucose and ketone monitoring while setting a regulatory path for future devices.
Contact Us
If you are a potential guest, a sponsor, or a listener with a question, we would love to hear from you.
Guest Enquiries — Speak on Pharmatica
We are always looking for senior pharmaceutical leaders and innovators with genuine expertise and current industry insight. Use the contact form to introduce yourself and the topics you are best placed to address.
Sponsorship — Partner with Us
Reach over 700,000 pharmaceutical and life sciences professionals. Contact us to discuss sponsorship and branded content opportunities.
Press & Media
For press enquiries, episode feedback, or editorial questions, write to us at info@pharmatica.io
